Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 4Phase 1 4Phase 1/2 2Phase 2/3 1

Status

Recruiting 4Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

OTHER 8INDUSTRY 8

Study Type

Interventional 8

Sponsor

Cancer Type

Breast 3Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 3Solid Tumors 1Ovarian Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Colorectal Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × inavolisib × Clear all
NCT07054190 2026-05-26

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
80 enrolled
Breast

Breast Neoplasms

NCT07368998 2026-05-11

optINAVO

Hoffmann-La Roche

Phase 2 Recruiting
80 enrolled
Breast

Breast Neoplasms

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

NCT07287150 2026-05-06

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting
176 enrolled
Gynecologic

Ovarian Neoplasms

NCT07323576 2026-02-09

INAVO-CRC

Hoffmann-La Roche

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed
252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡